Artiva Biotherapeutics Business Update
Artiva Biotherapeutics is implementing a wind-down of its operations, including the discontinuation of its AlloNK cell therapy candidate and a 94% reduction in workforce. The company estimates it will incur $27 million to $35 million in total charges, including up to $15 million for clinical trial close-out and up to $20 million for severance and termination costs. The workforce reduction is expected to be completed in the first quarter of 2027 as the company explores strategic alternatives.